p21-antisense enhances the NOD/SCID repopulation capacity and maintains differentiative ability of transduced CD34+ cord blood cells. CD34+ cord blood cells transduced with p21-antisense (p21-AS-V) or the control vector (GFP-V) were transplanted into sublethal irradiated NOD/SCID mice along with 2 × 106 irradiated carrier cells per mouse. At 8 to 12 weeks after transplantation the bone marrow was harvested and stained for the human leukocyte marker CD45 with myeloid and lymphoid differentiation markers (CD3, CD14, CD19, CD33, CD34, and CD38) and analyzed by flow cytometric analysis. (A) Chart shows the percentage of human CD45+ cells in the bone marrow of animals that underwent transplantation (thin line represents the mean). (B) Chart shows the proportion of differentiated cells in the CD45 subpopulation in the bone marrow of animals that received transplants of p21-antisense (p21-AS-V)– or control vector (GFP-V)–transduced cells (thin line represents the mean).
